• (16 Mar 2021) Enoxaparin- associated with lower rates of mortality than unfractionated Heparin

  April 7, 2021

  Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients https://doi.org/10.1016/j.eclinm.2021.100774 We find that COVID-19 patients administered unfractionated Heparin but not Enoxaparin have higher rates of 28-day mortality (risk ratio: 4.3; 95% Confidence Interval [C.I.].:… Continue reading "(16 Mar 2021) Enoxaparin- associated with lower rates of mortality than unfractionated Heparin"

• (04 Jan 2021) Enoxaprin- 60% reduction of mortality with higher doses

  January 6, 2021

  Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19 https://doi.org/10.1007/s11739-020-02585-9 Of 278 patients with Covid-19, 127 received prophylaxis with high enoxaparin doses and 151 with standard dosage. At 21 days, the incidence rate of death and clinical deterioration were… Continue reading "(04 Jan 2021) Enoxaprin- 60% reduction of mortality with higher doses"

• (11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality

  October 12, 2020

  Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients https://www.medrxiv.org/content/10.1101/2020.10.06.20208025v1 While retrospectively analyzing the complete electronic health records (EHRs) of 671 hospitalized COVID-19 patients administered either enoxaparin or unfractionated heparin,… Continue reading "(11 Oct 2020) Enoxaprin- associated with lower rates of thrombosis and mortality"